{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:25:13Z","timestamp":1790958313518,"version":"4.1.0"},"reference-count":47,"publisher":"Japan Endocrine Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1507\/endocrj.ej22-0241","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T22:18:56Z","timestamp":1664921936000},"page":"77-87","source":"Crossref","is-referenced-by-count":4,"title":["Self-reported symptoms in patients with acromegaly: a 6-month follow-up in a single neurosurgical center"],"prefix":"10.1507","volume":"70","author":[{"given":"Ben","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, 200040, China"},{"name":"National Center for Neurological Disorders, Shanghai, 200040, China"},{"name":"Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, 200040, China"},{"name":"Neurosurgical Institute of Fudan University, Shanghai, 200040, China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery, Shanghai, 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"He","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, 200040, China"},{"name":"National Center for Neurological Disorders, Shanghai, 200040, China"},{"name":"Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, 200040, China"},{"name":"Neurosurgical Institute of Fudan University, Shanghai, 200040, China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery, Shanghai, 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, 200040, China"},{"name":"National Center for Neurological Disorders, Shanghai, 200040, China"},{"name":"Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, 200040, China"},{"name":"Neurosurgical Institute of Fudan University, Shanghai, 200040, China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery, Shanghai, 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, 200040, China"},{"name":"National Center for Neurological Disorders, Shanghai, 200040, China"},{"name":"Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, 200040, China"},{"name":"Neurosurgical Institute of Fudan University, Shanghai, 200040, China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery, Shanghai, 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Shou","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, 200040, China"},{"name":"National Center for Neurological Disorders, Shanghai, 200040, China"},{"name":"Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, 200040, China"},{"name":"Neurosurgical Institute of Fudan University, Shanghai, 200040, China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery, Shanghai, 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, 200040, China"},{"name":"National Center for Neurological Disorders, Shanghai, 200040, China"},{"name":"Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, 200040, China"},{"name":"Neurosurgical Institute of Fudan University, Shanghai, 200040, China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery, Shanghai, 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengyi","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, 200040, China"},{"name":"National Center for Neurological Disorders, Shanghai, 200040, China"},{"name":"Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, 200040, China"},{"name":"Neurosurgical Institute of Fudan University, Shanghai, 200040, China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery, Shanghai, 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, 200040, China"},{"name":"National Center for Neurological Disorders, Shanghai, 200040, China"},{"name":"Shanghai Key Laboratory of Brain Function and Restoration and Neural Regeneration, Shanghai, 200040, China"},{"name":"Neurosurgical Institute of Fudan University, Shanghai, 200040, China"},{"name":"Shanghai Clinical Medical Center of Neurosurgery, Shanghai, 200040, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Melmed S (2006) Medical progress: acromegaly. N Engl J Med 355: 2558\u20132573.","DOI":"10.1056\/NEJMra062453"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Sherlock M, Ayuk J, Tomlinson JW, Toogood AA, Aragon-Alonso A, et al. (2010) Mortality in patients with pituitary disease. Endocr Rev 31: 301\u2013342.","DOI":"10.1210\/er.2009-0033"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Wolters TLC, Roerink SHPP, Sterenborg RBTM, Wagenmakers MAEM, Husson O, et al. (2020) The effect of treatment on quality of life in patients with acromegaly: a prospective study. Eur J Endocrinol 182: 319\u2013331.","DOI":"10.1530\/EJE-19-0732"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, et al. (2019) Acromegaly. Nat Rev Dis Primers 5: 20.","DOI":"10.1038\/s41572-019-0071-6"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Geraedts VJ, Andela CD, Stalla GK, Pereira AM, van Furth WR, et al. (2017) Predictors of quality of life in acromegaly: no consensus on biochemical parameters. Front Endocrinol (Lausanne) 8: 40.","DOI":"10.3389\/fendo.2017.00040"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 (1995) The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med 41: 1403\u20131409.","DOI":"10.1016\/0277-9536(95)00112-K"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Biermasz NR (2019) The burden of disease for pituitary patients. Best Pract Res Clin Endocrinol Metab 33: 101309.","DOI":"10.1016\/j.beem.2019.101309"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Guyatt GH, Feeny DH, Patrick DL (1993) Measuring health-related quality of life. Ann Intern Med 118: 622\u2013629.","DOI":"10.7326\/0003-4819-118-8-199304150-00009"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, et al. (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342: 1171\u20131177.","DOI":"10.1056\/NEJM200004203421604"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Jehle S, Reyes CM, Sundeen RE, Freda PU (2005) Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly. J Clin Endocrinol Metab 90: 1588\u20131593.","DOI":"10.1210\/jc.2004-1967"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Rubeck KZ, Madsen M, Andreasen CM, Fisker S, Frystyk J, et al. (2010) Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery. Eur J Endocrinol 163: 717\u2013726.","DOI":"10.1530\/EJE-10-0640"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Caron PJ, Bevan JS, Petersenn S, Houchard A, Sert C, et al. (2016) Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study. Pituitary 19: 149\u2013157.","DOI":"10.1007\/s11102-015-0693-y"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, et al. (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99: 3933\u20133951.","DOI":"10.1210\/jc.2014-2700"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Shen M, Yang Y, He W, Qiao N, He M, et al. (2020) Efficacy and predictors of short-term first-generation somatostatin analog presurgical treatment in acromegaly: a hospital-based study of 237 cases. Growth Horm IGF Res 55: 101354.","DOI":"10.1016\/j.ghir.2020.101354"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Shen M, Shou X, Wang Y, Zhang Z, Wu J, et al. (2010) Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocr J 57: 1035\u20131044.","DOI":"10.1507\/endocrj.K10E-203"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Albarel F, Castinetti F, Morange I, Conte-Devolx B, Gaudart J, et al. (2013) Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients. Clin Endocrinol (Oxf) 78: 263\u2013270.","DOI":"10.1111\/j.1365-2265.2012.04492.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Arafat AM, Mohlig M, Weickert MO, Perschel FH, Purschwitz J, et al. (2008) Growth hormone response during oral glucose tolerance test: the impact of assay method on the estimation of reference values in patients with acromegaly and in healthy controls, and the role of gender, age, and body mass index. J Clin Endocrinol Metab 93: 1254\u20131262.","DOI":"10.1210\/jc.2007-2084"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Gonzalez B, Vargas G, de Los Monteros ALE, Mendoza V, Mercado M (2018) Persistence of diabetes and hypertension after multimodal treatment of acromegaly. J Clin Endocrinol Metab 103: 2369\u20132375.","DOI":"10.1210\/jc.2018-00325"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19 American Diabetes Association (2014) Diagnosis and classification of diabetes mellitus. Diabetes Care 37 Suppl 1: S81\u2013S90.","DOI":"10.2337\/dc14-S081"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, et al. (2018) Systematic review for the 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71: 2176\u20132198.","DOI":"10.1016\/j.jacc.2017.11.004"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Shen M, Wang M, He W, He M, Qiao N, et al. (2018) Impact of long-acting somatostatin analogues on glucose metabolism in acromegaly: a hospital-based study. Int J Endocrinol 2018: 3015854.","DOI":"10.1155\/2018\/3015854"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Annamalai AK, Webb A, Kandasamy N, Elkhawad M, Moir S, et al. (2013) A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab 98: 1040\u20131050.","DOI":"10.1210\/jc.2012-3072"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Broersen LHA, Zamanipoor Najafabadi AH, Pereira AM, Dekkers OM, van Furth WR, et al. (2021) Improvement in symptoms and health-related quality of life in acromegaly patients: a systematic review and meta-analysis. J Clin Endocrinol Metab 106: 577\u2013587.","DOI":"10.1210\/clinem\/dgaa868"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, et al. (2007) Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156: 75\u201382.","DOI":"10.1530\/eje.1.02312"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, et al. (2008) Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 93: 3853\u20133859.","DOI":"10.1210\/jc.2008-0669"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, et al. (2009) The German ACROSTUDY: past and present. Eur J Endocrinol 161 Suppl 1: S3\u2013S10.","DOI":"10.1530\/EJE-09-0350"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Ghigo E, Biller BM, Colao A, Kourides IA, Rajicic N, et al. (2009) Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy. J Endocrinol Invest 32: 924\u2013933.","DOI":"10.1007\/BF03345774"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Trainer PJ, Ezzat S, D\u2019Souza GA, Layton G, Strasburger CJ (2009) A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) 71: 549\u2013557.","DOI":"10.1111\/j.1365-2265.2009.03620.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Sievers C, Brubach K, Saller B, Schneider HJ, Buchfelder M, et al. (2010) Change of symptoms and perceived health in acromegalic patients on pegvisomant therapy: a retrospective cohort study within the German Pegvisomant Observational Study (GPOS). Clin Endocrinol (Oxf) 73: 89\u201394.","DOI":"10.1111\/j.1365-2265.2009.03773.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Neggers SJ, Pronin V, Balcere I, Lee MK, Rozhinskaya L, et al. (2015) Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study. Eur J Endocrinol 173: 313\u2013323.","DOI":"10.1530\/EJE-15-0215"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25: 102\u2013152.","DOI":"10.1210\/er.2002-0022"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, et al. (2005) Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J Clin Endocrinol Metab 90: 3337\u20133341.","DOI":"10.1210\/jc.2004-1565"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Bonapart IE, van Domburg R, ten Have SM, de Herder WW, Erdman RA, et al. (2005) The \u2018bio-assay\u2019 quality of life might be a better marker of disease activity in acromegalic patients than serum total IGF-I concentrations. Eur J Endocrinol 152: 217\u2013224.","DOI":"10.1530\/eje.1.01838"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F (2005) Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 90: 2731\u20132739.","DOI":"10.1210\/jc.2004-2297"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Hua SC, Yan YH, Chang TC (2006) Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol 155: 831\u2013837.","DOI":"10.1530\/eje.1.02292"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, et al. (2004) Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 89: 5369\u20135376.","DOI":"10.1210\/jc.2004-0669"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Salvatori R, Maffei P, Webb SM, Brue T, Loftus J, et al. (2022) Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: a real-world experience. Pituitary 25: 420-432.","DOI":"10.1007\/s11102-022-01206-2"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Coopmans EC, El-Sayed N, Frystyk J, Magnusson NE, Jorgensen JOL, et al. (2020) Soluble Klotho: a possible predictor of quality of life in acromegaly patients. Endocrine 69: 165\u2013174.","DOI":"10.1007\/s12020-020-02306-4"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Bengtsson BA, Brummer RJ, Eden S, Bosaeus I, Lindstedt G (1989) Body composition in acromegaly: the effect of treatment. Clin Endocrinol (Oxf) 31: 481\u2013490.","DOI":"10.1111\/j.1365-2265.1989.tb01272.x"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Hansen TK, Moller J, Thomsen K, Frandsen E, Dall R, et al. (2001) Effects of growth hormone on renal tubular handling of sodium in healthy humans. Am J Physiol Endocrinol Metab 281: E1326\u2013E1332.","DOI":"10.1152\/ajpendo.2001.281.6.E1326"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Moller J, Nielsen S, Hansen TK (1999) Growth hormone and fluid retention. Horm Res 51 Suppl 3: 116\u2013120.","DOI":"10.1159\/000053173"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Vilar L, Vilar CF, Lyra R, Lyra R, Naves LA (2017) Acromegaly: clinical features at diagnosis. Pituitary 20: 22\u201332.","DOI":"10.1007\/s11102-016-0772-8"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, et al. (1994) Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 73: 233\u2013240.","DOI":"10.1097\/00005792-199409000-00001"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Zhang Z, Li Q, He W, Qiu H, Ye H, et al. (2018) The comprehensive impact on human body induced by resolution of growth hormone excess. Eur J Endocrinol 178: 365\u2013375.","DOI":"10.1530\/EJE-17-0872"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Giustina A, Gola M, Colao A, De Marinis L, Losa M, et al. (2008) The management of the patient with acromegaly and headache: a still open clinical challenge. J Endocrinol Invest 31: 919\u2013924.","DOI":"10.1007\/BF03346442"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Darendeliler F, Karagiannis G, Wilton P (2007) Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. Horm Res 68 Suppl 5: 41\u201347.","DOI":"10.1159\/000110474"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Nishioka H, Fukuhara N, Yamaguchi-Okada M, Takeshita A, Takeuchi Y, et al. (2017) Pitfalls in early biochemical evaluation after transsphenoidal surgery in patients with acromegaly. Endocr J 64: 1073\u20131078.","DOI":"10.1507\/endocrj.EJ17-0261"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/70\/1\/70_EJ22-0241\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T04:45:05Z","timestamp":1715316305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/70\/1\/70_EJ22-0241\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej22-0241","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023]]},"article-number":"EJ22-0241"}}